Market Place
Sourcing Support
Lupin Foundation Expands NCD Care Access In Rajasthan
10 Apr 2026 //
INDPHARMAPOST
Lupin Earns Global Great Place To Work Certification
07 Apr 2026 //
EXPRESSPHARMA
Lupin Completes Acquisition Of Visufarma
04 Apr 2026 //
PHARMIWEB
Zydus, Lupin Partner to Co-Market Semaglutide in India
17 Mar 2026 //
ECONOMICTIMES
Lupin Leads Global Pharma In S&P ESG Rankings
28 Feb 2026 //
INDPHARMAPOST
Lupin Gets US FDA EIR For Goa Facility With VAI Status
27 Feb 2026 //
PRESS RELEASE
Lupin CEO, Vinita Gupta Honored On 2026 CNBC Changemakers List
27 Feb 2026 //
PR NEWSWIRE
Lupin Signs Supply Deal To Launch Antidepressant In Canada
16 Feb 2026 //
PRESS RELEASE
Lupin Q3 FY26 Consolidated PAT Jumped 37.4% To Rs. 1,180.5 Cr
14 Feb 2026 //
PRESS RELEASE
Pharma Inc Urges Streamlined Regulatory Process For Growth Pill
09 Feb 2026 //
BUSINESS STD
Sun Pharma, Dr. Reddy`s, Lupin Advocate Major Drug Innovation
09 Feb 2026 //
ECONOMICTIMES
Lupin Founder`s Book `Made In India` Launched In Mumbai
09 Feb 2026 //
PRESS RELEASE
Lupin Earns Top ESG Rating For Climate And Water Security
23 Jan 2026 //
PRESS RELEASE
Lupin, Galenicum Sign Semaglutide Deal In 23 Countries
22 Jan 2026 //
PRESS RELEASE
Lupin and Gan & Lee Pharma Enter Exclusive Licensing Deal
29 Dec 2025 //
INDPHARMAPOST
Lupin Signs Licensing Deal With Neopharmed For Plasil
18 Dec 2025 //
PRESS RELEASE
Lupin Receives EIR from US FDA for its Nagpur Injectable Facility
18 Dec 2025 //
PRESS RELEASE
Lupin Secures Sbti Validation For Emission Reduction Targets
17 Dec 2025 //
INDPHARMAPOST
Lupin Manufacturing Solutions partners with PolyPeptide
12 Dec 2025 //
PRESS RELEASE
Lupin, TPG, EQT Eye Lalvani Family-Owned Vitabiotics
01 Dec 2025 //
ECONOMICTIMES
Lupin Foundation Achieves CRISIL`s Highest VO 1A Rating
29 Nov 2025 //
INDPHARMAPOST
FDA Inspects Lupin`s Nagpur Unit-1, Finds No Issues
15 Nov 2025 //
PRESS RELEASE
Lupin Achieves S&P Global ESG Score Of 91
14 Nov 2025 //
INDPHARMAPOST
Lupin Surpasses Pharma Industry Average With S&P Global ESG
13 Nov 2025 //
EXPRESSPHARMA
Lupin Receives EIR From FDA For Its Aurangabad Facility
13 Nov 2025 //
PRESS RELEASE
Lupin Q2 PAT Rises 73% on Strong Growth Across Key Global Markets
06 Nov 2025 //
BUSINESS STD
Lupin Receives EIR From US FDA For Its Pithampur Unit-3 Facility
06 Nov 2025 //
PRESS RELEASE
Lupin Inaugurates New Headquarters In Bridgewater, NJ
28 Oct 2025 //
PRESS RELEASE
Lupin To Lay Out $250M For New Fla. Manufacturing Facility
10 Oct 2025 //
PRESS RELEASE
Lupin Launches Partnership to Expand Long-Acting Injectables
09 Oct 2025 //
PR NEWSWIRE
Lupin To Build $250 Million Manufacturing Facility In Florida
08 Oct 2025 //
INDPHARMAPOST
Lupin Acquires Visufarma To Enhance Ophthalmology Portfolio
30 Sep 2025 //
PRESS RELEASE
Lupin carves out LupinLife Consumer Healthcare
02 Jul 2025 //
INDPHARMAPOST
Lupin, Sino Universal Sign Agreement for Tiotropium DPI in China
17 Jun 2025 //
INDPHARMAPOST
Lupin to Present Phase 1 Data on LNP7457 at ASCO Meeting 2025
27 May 2025 //
INDPHARMAPOST
Novartis Offers Payment Plan for High-Cost Heart Medicine
27 May 2025 //
ECONOMICTIMES
Lupin partners Honeywell for HFO technology in Inhalers
21 May 2025 //
EXPRESSPHARMA
Lupin posts consolidated Q4 FY25 PAT at Rs. 772.52 Cr
16 May 2025 //
INDPHARMAPOST
Supply chain leadership: Stepping into the spotlight
08 May 2025 //
EXPRESS PHARMA
Indian pharma stocks decline after Trump again threatens tariffs
09 Apr 2025 //
REUTERS
Lupin announces acquisition of Renascience Pharma for 12.3M
05 Apr 2025 //
BUSINESS STD
Lupin bags EcoVadis Silver Medal for sustainability excellence
21 Mar 2025 //
INDPHARMAPOST
Lupin In S&P Global Sustainability Yearbook 2025 Second Year
02 Mar 2025 //
EXPRESSPHARMA
Nifty Pharma Tanks 3% on Tariff Threat; Zydus, Lupin Down 10%
19 Feb 2025 //
BUSINESS STD
Lupin Q3 FY25 profit up 40% at Rs. 855 Cr
14 Feb 2025 //
INDPHARMAPOST
Lupin and Avas launch NaMuscla in Italy
29 Jan 2025 //
EXPRESSPHARMA
Lupin acquires Huminsulin from Lilly, enhance diabetes portfolio
31 Dec 2024 //
INDPHARMAPOST
Lupin’s Humrahi Diabetes Support Program Expands To Heart Health
28 Nov 2024 //
FINANCIALXPRESS
Lupin’s ESG score rises to 76 in S&P Global ESG Ratings
25 Nov 2024 //
EXPRESSPHARMA
Lupin launches Humrahi with focus on diabetes and heart health
18 Nov 2024 //
EXPRESSPHARMA
Lupin Eyes Double-Digit Growth, Focuses on US Market in FY25
09 Nov 2024 //
CNBCTV
Lupin CFO: Medicine Business Benefits from Supply Chain Diversify
08 Nov 2024 //
CNBC
Lupin Develops Inhalers with Near-Zero Global Warming Propellants
28 Oct 2024 //
PR NEWSWIRE
Lupin appoints Claus Jepsen as President of Global Specialty
22 Oct 2024 //
EXPRESSPHARMA
Lupin and Scope sign agreement for Optase in Mexico
08 Oct 2024 //
INDPHARMAPOST
Lupin acquires 9 brands of Medical Nutritional Institute in Africa
05 Oct 2024 //
EXPRESSPHARMA
Aytu Partners With Lupin To Commercialize ADHD Drugs In Canada
01 Oct 2024 //
ACCESSWIRE
Lupin Signs Distribution Agreement With Scope Ophthalmics
01 Oct 2024 //
EXPRESSPHARMA
Lupin Ties Up With Scope Opthalmics To Market Eyecare Products
30 Sep 2024 //
ECONOMICTIMES
Lupin inks pact with Celnova Pharma for distribution of drug
28 Sep 2024 //
ECONOMICTIMES
